Related Experiment Video
Updated: Oct 18, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Effect of Financial Incentives for Process, Outcomes, or Both on Cholesterol Level Change: A Randomized Clinical
Peter P Reese1,2,3,4,5, Iwan Barankay4,6, Mary Putt1,4
1Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Financial incentives targeting medication adherence or cholesterol levels did not significantly lower LDL-C in adults at high cardiovascular risk. This study found no added benefit from process-plus-outcomes incentives compared to control for improving cholesterol levels.
Area of Science:
- Cardiovascular disease prevention
- Behavioral economics in health
- Clinical trial methodology
Background:
- Financial incentives are explored to enhance health behaviors, but their effectiveness in targeting specific processes versus outcomes remains unclear.
- Understanding the impact of different incentive structures on low-density lipoprotein cholesterol (LDL-C) reduction is crucial for cardiovascular health.
Purpose of the Study:
- To compare the efficacy of financial incentives for medication adherence (process), LDL-C level reduction (outcomes), or both, against a control group in lowering LDL-C levels.
- To investigate if financial incentives influence key health behaviors and clinical outcomes in adults at high risk for atherosclerotic cardiovascular disease.
Main Methods:
- A randomized clinical trial involving 764 adults with elevated cardiovascular risk and suboptimal LDL-C levels was conducted over 12 months.
- Participants were assigned to receive daily incentives for adherence, quarterly incentives for LDL-C reduction, or a combination, alongside standard care.
- Adherence was monitored using smart pill bottles, and LDL-C levels were measured quarterly.
Main Results:
- All incentive groups showed reductions in LDL-C levels, but these were not statistically significantly greater than the control group.
- Mean LDL-C reductions ranged from -36.9 mg/dL in the control group to -42.8 mg/dL in the process plus outcomes group.
- Exploratory analyses found no significant impact on hemoglobin A1c or blood pressure in participants with diabetes and hypertension.
Conclusions:
- Financial incentives, whether targeting medication adherence, LDL-C outcomes, or both, did not demonstrate superior effectiveness in reducing LDL-C levels compared to standard care in this trial.
- The findings suggest that current financial incentive models may not be a potent strategy for improving LDL-C levels in this high-risk population.
Related Concept Videos
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cholesterol: Significance and Regulation
Considering cholesterol and...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Clinical Trials
There are four phases in a clinical trial. A phase one...

